AAC, added several thousand shares in the $7 range Stable revenue growth, books will lean out over the next couple years as legal costs diminish, properties and debts are paid off. They are in a good position to capitalize off the drug epidemic trend of the past 20 years and more so recently. Also, they have a stable De Novo pipeline.